The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
The secondary objectives of the study are:
- To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population
- To characterize concentrations of casirivimab and imdevimab in serum over time
- To assess the immunogenicity of casirivimab and imdevimab
outside the clinical trial.